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Results
• Rifampicin is the mainstay of 1 st line tuberculosis (TB) treatment
• Rifampicin, which is hepatically cleared, induces its own metabolism (autoinduction) and undergoes extensive first-pass metabolism [1]
• The onset and extent of auto-induction have not been adequately described
• Saturation of hepatic extraction of rifampicin at higher doses has been reported [2] and characterising the process becomes important if the dose of rifampicin is to be increased Objectives 1. To describe rifampicin PK among TB patients accounting for auto-induction of clearance and saturation of hepatic extraction using a population model 2. Explore changes in exposure when dose is increased beyond currently recommended level
Background and Objectives
Data:
• 61 (33 females) HIV/TB co-infected and treatment naïve patients from South Africa commenced weight-adjusted doses (10 mg/kg on week days; 10 patients received treatment every day) of rifampicin as part of TB treatment.
• Blood samples were collected pre-dose, and at 1, 2, 4, 6, 8 and 12 hours post dose on each PK sampling day i.e. day 0, 7, 14 & 28 • Demographic data of 870 TB patients from South Africa & West Africa were used to simulate higher doses of rifampicin 
Methods

Conclusions
Model predicts that increasing the dose of rifampicin result in a more than proportional increase in exposure, similar to recent report on high dose rifampin [5]
Auto-induction of rifampicin clearance is almost complete after 3 weeks of treatment initiation
With the currently recommended dose of rifampicin, the model predicts saturation of hepatic extraction and larger exposures in patients with higher weight (and proportionally lower FFM), as previously observed [6] The potential for increased toxicity with the nonlinear increase in rifampicin exposures warrants thorough investigation More work is needed to investigate whether higher rifampicin doses may lead to more pronounced induction Model building: Model structure is in Figure 1 and final parameter estimates in Table 2 *Numbers in bracket are the 5 th and 95 th percentiles of the distribution of simulated AUCs
